University of Texas Southwestern Medical Center, Dallas, Texas.
University of Texas Southwestern Medical Center, Dallas, Texas.
J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1489-1499. doi: 10.1016/j.jaip.2017.05.018. Epub 2017 Jul 19.
Chronic urticaria (CU) is the occurrence of urticaria with or without angioedema for at least 6 weeks. Management has traditionally involved antihistamines as first-line therapy with various alternative therapies for refractory cases. Largely based on the success of biologics for various diseases, this class of drugs has come to the forefront of medical research. The first and only Food and Drug Administration-approved biologic for the management of CU is omalizumab (humanized anti-IgE mAb). In the past decade, a substantial amount of research has been centered on the mechanism of action, efficacy, dosing, and safety of omalizumab. This review will focus on the data surrounding the management of CU with omalizumab, off-label use of other biologics for CU, and biologics currently under investigation for use in CU. We will also discuss management considerations and areas of interest for future research.
慢性荨麻疹（CU）是指荨麻疹或伴有血管性水肿，持续至少 6 周。传统上，管理涉及抗组胺药作为一线治疗，对于难治性病例有各种替代疗法。在很大程度上基于生物制剂在各种疾病中的成功，这类药物已成为医学研究的前沿。第一个也是唯一获得美国食品和药物管理局批准用于治疗 CU 的生物制剂是奥马珠单抗（人源化抗 IgE mAb）。在过去的十年中，大量的研究集中在奥马珠单抗的作用机制、疗效、剂量和安全性上。本综述将重点讨论奥马珠单抗治疗 CU 的相关数据、CU 的其他生物制剂的标签外使用以及目前正在研究用于 CU 的生物制剂。我们还将讨论管理注意事项和未来研究的兴趣领域。
